Proximity ligation 2 and proximity extension assays 3 (PLA and PEA, respectively) can address the above limitations by offering a means to construct highly sensitive and specific detection reactions for sets of protein variants or protein complexes. These assays use sets of affinity reagents that are directed against proteins of interest and modified through the addition of short DNA strands, referred to
as PLA probes. Upon joint detection of a target protein or protein complex by two or more such affinity reagents, the attached DNA strands are brought in sufficient proximity to undergo joint enzymatic reactions, i.e., ligation or polymerization reactions. These enzymatic reactions are designed to give rise to DNA products that can be detected via amplification reactions, whereas any unreacted probes fail to give rise to detection signals.
Proximity-based detection reactions differ from immuno-PCR 4 or immune rolling-circle amplification (RCA) techniques 5 . In contrast to these earlier techniques, proximity reactions depend on the simultaneous recognition of target molecules by two or more oligonucleotide-modified affinity reactions in order to trigger the formation of amplifiable reaction products. Therefore, individual detection reagents fail to be detected, thus avoiding background from single nonspecifically bound reagents.
Proximity reactions have been designed for localized detection in cells or tissues of single proteins, of colocalized pairs of proteins or of post-translationally modified proteins via in situ PLA 6 . In these reactions, oligonucleotides attached to pairs of antibodies with bound target epitopes in close proximity are used to template the formation, via ligation, of DNA circles that are then locally amplified via RCA reactions.
Both PLA and PEA reactions can be configured to detect individual or panels of proteins present in solution without the need for a solid phase or for washes 2, [7] [8] [9] [10] . In these assays, the incubation of a sample with PLA probes is followed by a dilution step to increase the average distance between any PLA probes that have failed to bind jointly to a target molecule. This serves to reduce background. By contrast, pairs of PLA probes that remain in proximity by having bound a target molecule can now undergo enzymatic reactions that create reporter DNA strands for subsequent Solid-phase proximity ligation assays for individual or parallel protein analyses with readout via real-time PCR or sequencing amplification reactions. PEA and in situ PLA assays are commercially available from Olink Bioscience.
In the case of PLA, oligonucleotides attached to antibodies that have both bound their target are joined by ligation by adding a connector oligonucleotide and a ligase. In PEA, the antibody-bound oligonucleotides undergo a templated polymerization reaction in which one of the oligonucleotides serves as a primer and the other as a template. In both assays, the target protein-specific reporter strands that form are typically quantified via real-time PCR.
Here we provide protocols for another form of PLA, namely solid-phase PLA (spPLA) 11 , which offers highly specific and sensitive detection of single or multiple proteins in, e.g., blood plasma, cerebrospinal fluid or in tissue lysates by requiring recognition of target molecules by sets of three antibodies. An illustration of spPLA can be found in Figure 1 .
Overview of the procedure
In spPLA 11 , antibodies are first immobilized on a solid support, acting as capture agents for the proteins of interest (Fig. 1a) . After protein capture, the solid phases are washed to remove matrix constituents that might contribute to background noise or interfere with binding reactions, enzymatic steps or recording of signals. Subsequently, captured proteins are detected using pairs of antibodies that have been conjugated to distinct oligonucleotides (Fig. 1b) . Upon binding, washes are performed to remove unbound detection reagents to avoid target-independent reaction products. Oligonucleotides on pairs of PLA probes that have been brought in proximity owing to antigen recognition are then allowed to hybridize to a short connector oligonucleotide, so that the antibody-conjugated oligonucleotides can be joined by enzymatic ligation (Fig. 1c) . Ligation products are then detected and quantified with qPCR or NGS, thus revealing protein concentrations according to the abundance of each specific ligation product (Fig. 1d) .
spPLA is suitable for analyzing sample volumes from a few microliters to several milliliters. The unique requirement for recognition by three antibodies serves both to reduce background due to nonspecifically bound detection reagents and to minimize cross-reactions for irrelevant, even closely related molecules. The assay can be used to investigate a single protein species, and it can also be adapted for parallel detection of multiple proteins without an increasing risk of nonspecific reaction products associated with multiplexing. This is possible because the reagents can be designed such that only the correct combinations of PLA probes can give rise to ligated reporter strands 12 . Finally, reporter-strand detection via next-generation sequencing provides a digital readout for greater assay precision compared with assay readouts where intensities or threshold cycles are used as measures of protein amounts. An overview of the described protocol is shown in Figure 2 .
Applications of the method spPLA has been used to detect many different proteins in serum or plasma. Assay sensitivity is typically in the low-picomolar range, most often resulting in an improved sensitivity of detection compared with sandwich immunoassays, sometimes by as much as three orders of magnitude using the same affinity-purified polyclonal antibody preparation 11 .
By using spPLA, concentrations of the protein GDF-15 have been measured in clinical samples with very good reproducibility in an investigation lending further support to the role of this protein as a marker for coronary artery disease 12 . A multiplex version of spPLA has been used to simultaneously detect up to 36 proteins in order to identify diagnostic biomarkers for colorectal cancer 13 and cardiovascular disease 12 . In addition, up to 48 proteins have been analyzed using multiplex spPLA for the identification of biomarkers for chronic pain and Alzheimer's disease (A.
The assay has also been used to detect amyloid-β (Aβ) protofibrils, efficiently discriminating between monomeric and aggregated forms of the protein and achieving a 25-fold improved sensitivity compared with a sandwich ELISA using the same monoclonal antibody 14 . Furthermore, spPLA can detect complex targets such as a form of microvesicles referred to as prostasomes 15 , by using a variant of the assay in which a combination of four antibodies The initial three steps of the protocol are in common for both the singleplex and multiplex version of the protocol. When a single protein is detected, ligation and PCR detection are performed simultaneously, after the incubation of beads with PLA probes (purple). When multiple proteins are detected, ligation is performed separately, followed by universal PCR preamplification (red). Preamplified products are either prepared for sequencing (green) or for readout using real-time PCR (blue).
is used as a PLA probe. In this way, very low concentrations of prostasomes were detected in blood of patients with different stages of prostate cancer, thereby identifying these structures as promising diagnostic biomarkers that can potentially distinguish patients with different histological grades of malignancy. spPLA has furthermore been used to detect biosecurity agents 16 ; interacting proteins 17 ; and, via an inhibition format, low concentrations of low-molecular-weight molecules 18 .
Proximity-based immunoassays can be used when specific and sensitive detection is required. The assay can be multiplexed and miniaturized to allow for high-throughput biomarker validation in large sample cohorts, and it is expected to be of value for diagnostic applications and in drug development. Suitably modified assay formats could also render the assays useful for diagnostics at the point of care.
Comparison with other methods
Mass spectrometry is by far the most powerful method for analyzing thousands of proteins in a single run, but it remains limited in sensitivity for highly complex proteomes such as that of blood plasma 19 . The problems can be mitigated by sample depletion and fractionation before analysis, as well as by integration of affinity enrichment 20 with selective reaction monitoring 21 . Combinations of the above have resulted in very sensitive mass spectrometry assays, but at the expense of multiplexing and sample throughput 22 . PLA belongs to a class of next-generation immunoassays with increased sensitivity, specificity and/or suitability for multiplexing. Compared with standard colorimetric or fluorescent sandwich immunoassays, spPLA has improved sensitivity as a result of successful background suppression, owing to the use of PCR for amplified detection as well as to the requirement for multiple recognition events in order to generate detection signals.
Compared with other highly sensitive DNA-based assays such as immuno-PCR 4 or bio-barcode assays 23 , an advantage of spPLA is the requirement for multiple recognitions to generate amplifiable reporters, and the potential for multiplexing without compromising the sensitivity or specificity of detection. We have demonstrated experimentally that unspecific background increases only minimally when many proteins are detected in parallel, thus allowing assay performance to be maintained with multiplexing, in contrast to the use of sandwich assays 12 . Although the homogeneous solutionphase proximity ligation or extension assays have a simple workflow because there are no washes, spPLA can offer a number of advantages. The opportunity to perform washes of molecules captured on the solid support means that excess affinity reagents and sample components that interfere with detection can be removed. It also means that sample volumes larger than the 1 or 2 µl used in the homogeneous assays can be used, something that can be of value for enhancing detection sensitivity, dynamic ranges and avoiding stochastic noise. Finally, the spPLA goes beyond the more standard sandwich assays and homogeneous proximity assays with the requirement that three different affinity reagents all recognize each target molecule, which adds specificity and the ability to distinguish closely similar molecules.
As discussed, spPLA can also be used to specifically investigate classes of molecules that may be inaccessible to analysis by other methods such as aggregated 14 or interacting proteins 17 , and large particulate structures such as microvesicles or exosomes 15 .
Limitations
As with any immunoassay, the performance of spPLA is highly dependent on the quality of the affinity reagents. Despite the fact that the assay design allows the influence of cross-reactive events to be minimized, optimal assay performance mandates the use of specific binders of high affinity. In addition, given the requirement for multiple antigen recognition, sets of compatible monoclonal binders or polyclonal binders capable of recognizing several epitopes of the antigen without steric hindrance must be used.
Typical spPLA coefficients of variation are approximately 20-25%, limiting precise quantification. A large part of this variation is the result of the PCR step, which can be highly variable at low target copy numbers. Other amplification methods such as RCA have been used, enabling linear signal amplification and digital quantification by counting RCA products, thereby resulting in improved assay precision 16 .
Experimental design General considerations. spPLA is designed to achieve a high degree of specificity of protein detection by using three independent target-recognition events. Accordingly, the assay is well suited for analysis of proteins, ranging from small cytokine molecules to larger proteins, present at low concentrations in complex biological matrices. spPLA is also suitable for detecting targets such as protein complexes, proteins bearing post-translational modifications, and intact viruses and bacteria. It is also possible to reconfigure the assay architecture to detect more complicated targets, such as microvesicles or exosomes, by requiring four or more target recognizing events 15 . This protocol describes a triple-binder spPLA for the detection of proteins individually and in multiplex.
There are two main options with respect to the choice of solid support for spPLA: microtiter plates and microparticles. Both perform equally well for detecting single protein species; however, the microparticle-based protocol has better reaction kinetics and is more suitable for multiplex assays.
For a typical spPLA protocol, we recommend using solid phases with hydrophobic surfaces; however, hydrophilic surfaces may be suitable in specific cases. When you are using polyclonal antisera both for capture and detection, antibodies should be immobilized with an empirically adjusted antibody density in order to avoid blocking excessive numbers of epitopes by the capture antibodies. Unspecific background signals tend to be proportional to the total surface area used. It is thus important to maintain a balance between efficient capture and surface area. As spPLA uses antibodies coupled to DNA oligonucleotides, it is important that blocking agents include antisera from the same species as the detection antibodies, as well as oligonucleotide-blocking compounds such as sheared salmon sperm DNA.
The incubation time for the initial target capture or the subsequent detection depends on the affinity of antibody-antigen interaction. In a typical case, incubation for 1-2 h at room temperature (RT, 20-25 °C) is sufficient. Longer incubation times may result in increased background, whereas shorter incubation time may result in signal reduction and increased assay variation. It is usually sufficient to remove excess reagents from previous steps by two washes with PBS-T. However, different targets or biological matrices may require modified washing procedures.
The individual and multiplex spPLA protocols described herein use two different DNA ligases. These ligases have different temperature optima and sequence preferences and may differ in efficiency and specificity. Therefore, deviations from the protocol we describe should be properly validated. In addition, reduced ligation times may result in loss of signals owing to incomplete ligation, whereas longer ligation incubation time at high temperature (e.g., 50 °C) can result in loss of signals from dissociation of antigen and antibodies. Enzyme solutions should be freshly prepared before use.
Affinity reagents. As mentioned above, sets of affinity reagents for any target protein should be capable of recognizing at least three nonoverlapping epitopes. In practice, we have a good success rate using affinity-purified polyclonal antibodies raised against whole proteins, as these typically include specificities directed against several epitopes. Alternatively, sets of three monoclonal reagents that bind distinct epitopes of the protein are also suitable, or combinations of monoclonal and polyclonal reagents. In spPLA, antibodies must be modified, for example, by biotinylation for binding to streptavidin-oligonucleotide conjugates or by direct covalent conjugation to oligonucleotides. There is a risk, however, that the antigen-binding ability of an affinity reagent is disrupted by the conjugation. We therefore recommend that new conjugates be validated by analyzing dilutions of known amounts of the target protein. This is also helpful for estimating absolute amounts of target proteins in unknown samples by reference to results from analysis of the standard curve.
Sample types. spPLA performs robustly in various sample types, such as plasma, serum, whole blood, cerebrospinal fluid, brain homogenates, and tissue and cell lysates. Typically, 5-µl sample aliquots are used for each assay. To eliminate potential matrix interference, it may be helpful to perform an extra matrix depletion step by first removing irrelevant substances binding to the solid phase through a first incubation with microparticles without capture antibodies, or samples can be simply diluted tenfold before incubation with the capture supports.
Detection of ligation products. DNA ligation products can be detected by real-time PCR, either using specific TaqMan probes or nonspecific intercalating dyes such as SYBR Green. Ligation products can also be enumerated using NGS Technologies. To compensate for wide differences in the amounts of different targeted proteins for NGS readout, it can be helpful to adjust the concentrations of detection reagents so that less ligation products are generated for more abundant proteins.
Design of oligonucleotides.
The reagents required for the detection of a protein by spPLA include five or six different oligonucleotides: two oligonucleotides for each pair of PLA probes, one ligation template, two PCR primers, and, if desired, also one TaqMan probe. If the ligation products are to be detected by NGS, sample tags and index motifs required by the particular sequencer must be introduced. Oligonucleotides should have minimal complementarity to extraneous sequences that may be present in the investigated sample. We recommend using BLAST or other in silico means to exclude the presence of such sequences. Furthermore, oligonucleotides should be of high purity and quality. Longer oligonucleotides can be ordered from commercial vendors that offer HPLC or PAGE purification.
Newly designed oligonucleotides for PLA probes or PCR primers should be tested before use to assess ligation and amplification efficiency and specificity. Each oligonucleotide category is described in greater detail below and graphically explained in Figure 3 .
Oligonucleotides for PLA probes. Typically, the oligonucleotides coupled to antibodies are single-stranded DNA molecules between 50 and 60 nt in length, with a balanced GC-to-AT ratio. The oligonucleotides include two general functional motifs: sequence elements that allow the oligonucleotide to be joined via enzymatic ligation by hybridizing to a common connector oligonucleotide, and PCR primer-binding sites. In the case of multiplex PLA, each oligonucleotide includes two PCR primer sites in tandem: one universal site that is common to all PLA probe pairs and one specific site for each cognate PLA probe pair. The specific primer sites can also be used to identify correct ligation products after sequencing and are usually 20 nt long. Individual PLA oligonucleotides should be tested in silico to ensure minimum secondary structure by DNA-folding analysis tools (e.g., Mfold). A pair or set of PLA oligonucleotides should be tested to ensure minimum nonspecific hybridization and selftemplated ligations by using multiple sequence alignment tools (e.g., ClustalW). To avoid contamination of oligonucleotides before conjugation, we recommend ordering the members of each pair of PLA oligonucleotides from two different commercial vendors. The oligonucleotides that participate in the ligation reaction via their 5′ ends must be phosphorylated. Ligation template. The ligation template is designed to preferentially permit hybridization to oligonucleotides on PLA probes that have been brought in proximity. Each member of a PLA probe pair has a 10-nt-long hybridization sequence at its free ends, bringing the length of the hybridization template to 20 nt. This design is amenable to ligation with either Ampligase or T4 DNA ligase. In multiplex PLA, we have made use of a 'sliding-splint' design, allowing only the correct pairs of PLA probe oligonucleotides to be ligated, although all pairs can hybridize to a single ligation template. In this manner, only correct pairs of oligonucleotides are correctly positioned to be ligated, as the junction of each oligonucleotide pairs are all offset by at least one nucleotide from any other pair (Fig. 3) . With a hybridization sequence of each PLA probe pair member of 10 nt in length, a ligation template that is n nucleotides long (n > 20) can template ligation for n-20 unique oligonucleotide pairs. It is important to avoid nonspecific PCR amplification owing to extension of the PLA oligonucleotides by the ligation template. We have used two different approaches to avoid this risk: in the singleplex spPLA protocol, the ligation template is extended with a three-nucleotide-long noncomplementary sequence at each end, whereas in the multiplex PLA protocol T residues in the connector oligonucleotide are replaced by U residues. This allows the degradation of the ligation template before PCR using the enzyme uracil-DNA glycosylase (UDG). By replacing thymidine triphosphate with deoxyuridine triphosphate during PCR, this enzymatic step also serves to remove any PCR contaminants. To ensure that only the correct combinations of PLA probes can give rise to detectable reaction products in multiplex spPLA, we use the above slidingsplint design for the ligation template. Besides this 'constrained ligation', primer pairs used for real-time PCR detection of protein-specific DNA reporters are also selected so that only the cognate pairs of PLA probes can give rise to amplification products. When reaction products are detected through NGS, any noncognate pair of tags that may be recorded can be discounted as acts of cross-reactivity. PCR primers. Primer design for spPLA follows guidelines for other PCR-based assays 24 . Specific PCR primers in multiplex PLA should be tested in silico and in vitro for minimum interactions. TaqMan probe. TaqMan probe design for spPLA follows guidelines for other real-time PCR-based assays (e.g., http://www.premierbiosoft.com/). Sequencing oligonucleotides. Ligation products from spPLA can be identified using any NGS instrument, and besides proteinspecific motifs the reporter strands can be modified to also include sample tags, added after the spPLA reaction to permit pooling of ligation products from many different analyzed samples. We have used two sets of oligonucleotides to prepare a sequencing library: one set of index primers that include motifs required by the particular sequencer and a sample index, and PLA primers used to label ligation products by PCR. In addition, one set of enrichment primers composed of sequencer-specific primers to enrich indexed ligation products by PCR is used.
PLA probe conjugations.
A number of different protocols are available for coupling antibodies to oligonucleotides. Briefly, we have mainly used two approaches: biotin-streptavidin-mediated coupling 11 and covalent conjugation by the use of hetero-bifunctional linkers 12 . Streptavidin-linked oligonucleotides, as well as antibody-DNA conjugates and commercial conjugation kits, can also be purchased from commercial vendors.
• • • Controls and calibration curves. We recommend the inclusion of positive and negative controls with every experiment. Calibration curves of dilutions of recombinant antigens in buffer or a nonhumanderived relevant matrix such as chicken serum or plasma can serve as positive controls. For most assays, the dilution series should cover concentrations starting from 1 or 10 nM to low-fM concentrations. The same diluent without the protein of interest serves as a negative control. To exclude template-independent amplification by the PCR primers, PCR can be attempted in the absence of added template or ligase.
To avoid saturation during universal PCR amplification after multiplex spPLA, and for normalization purposes, PLA reagents for an added protein control should be included, such as mouse IgG for the analysis of human samples, with the same concentration of the control added to each sample. The concentration of such spiked-in internal controls should be within the dynamic range of spPLA. For example, mouse IgG was spiked in every sample at a concentration of 10 pM in our previous studies of human protein biomarkers 12 .
Raw data acquisition. Real-time PCR data are exported as values of threshold cycle (C t ) using each instrument's built-in software. For further analysis, we recommend the conversion of the reverse and logarithmic C t scale to a more convenient linear scale. This can be done using the following equation:
where M a is the number of PCR amplicons, E is the efficiency of replication in each PCR cycle, Ct 1 the number of PCR cycles required to bring an individual amplicon to the threshold for fluorescence detection and Ct a is the C t value of each sample. The formula can be used without the intention to convert C t values to actual numbers of molecules, and thus values for E and Ct 1 may be set arbitrarily without affecting the analysis. If exact conversion is required, then experimentally deduced values of E and Ct 1 should be used.
Reads obtained from DNA sequencing are first sorted according to the presence of sample indices, and then mapped to a reference library consisting of all the expected ligation products, counting the occurrence of each ligation product as a measure of the amounts of specific proteins present in this sample. Depending on the performance of the sequencing technology used, numbers of allowed mismatches in the alignment of obtained reads can be varied to obtain the best results. Only uniquely mapped reads are used for subsequent analysis.
Data analysis and quantification. Absolute concentrations of target proteins can be inferred using calibration curves. Calibration curves are constructed by plotting numbers of detected amplicons as converted from C t values versus the concentration of each protein standard by regression analysis. We recommend plotting data using log/log axes. If samples have been diluted, the concentration calculated from calibration curves should be multiplied by the dilution factor.
For multiplex PLA, data of each individual sample should be normalized against its spike-in control value. We use numbers of starting amplicons directly for further analysis. 
3|
Wash the microparticles by removing the tube from the magnet and resuspending it with 500 µl of washing buffer. Place the tube on the magnet for 30 s and discard the washing buffer. Repeat this step once.
4|
Dilute the biotinylated antibody to 50 nM in storage buffer.
5|
Add 200 µl of 50 nM biotinylated antibody into the tube containing the microparticles, and then incubate it on an end-over-end rotator at a speed of 16-20 r.p.m. for 1 h at RT.  crItIcal step When polyclonal antibodies are used as capture agents, signals decrease when the amount of antibody exceeds approximately one-tenth of the bead total capacity stated by the manufacturer. We believe that this is due to excessive epitope occupancy by the immobilized antibody, resulting in reduced epitope availability for the detection antibodies. We thus recommend using the suggested antibody coating density. In case that capture antibody concentration needs to be adjusted, we recommend titrations of capture antibody using the suggested amount of beads. We recommend the use of a positive and negative control to assess at which concentration the signal-to-noise to ratio is maximized.
6|
Place the tube on a magnet for 30 s and discard the supernatant.
7|
Wash the microparticles with 500 µl of washing buffer twice as described in Step 3.
8|
After the last wash of microparticles in Step 7, resuspend the microparticles in 200 µl of storage buffer.
9|
For preparing microparticles for the multiplex PLA, repeat Steps 1-8 separately for each additional antibody.  pause poInt Functionalized beads can be stored at 4 °C for up to 6 months.
conjugation of oligonucleotides on antibody • tIMInG 10 h 10| Dilute 20 µg of antibody in 10 µl of 1× PBS.
11| Prepare a fresh solution of 4 mM sulfo-SMCC in DMSO.
 crItIcal step Sulfo-SMCC solution should always be freshly prepared before antibody functionalization.
12| Add 1 µl of dissolved sulfo-SMCC from Step 11 to the antibody from Step 10. Mix gently and incubate at RT for 2 h.
13|
Freshly dissolve DTT in conjugation buffer to a final concentration of 100 mM.  crItIcal step DTT solution should always be freshly prepared before oligonucleotide reduction.
14| Mix 4 µl of the thiol-modified oligonucleotides (100 µM in water) with 11 µl of conjugation buffer and 15 µl of dissolved DTT from Step 13. Let the reduction proceed for 1 h at 37 °C.  crItIcal step The antibody activation and oligonucleotide reduction reactions should finish at the same time. To achieve this, initiate the reduction after ~1 h of activation.
15| Separately buffer-exchange the antibody and the oligonucleotides to conjugation buffer using Zeba columns or plates according to the manufacturer's recommendations.
16|
Mix the collected antibody with the oligonucleotide.
17|
Place the product of Step 16 into a 7-kD cutoff dialysis cup. Dialyze the product overnight at 4 °C against 5 liters of 1× PBS with constant stirring.  crItIcal step Dialysis should be performed immediately after mixing the activated antibody and oligonucleotides reduced by treatment with DTT.
18| Collect the conjugates from the dialysis cup and adjust the volume to 100 µl with storage buffer.  crItIcal step Antibodies that will undergo conjugation should be in buffer without free amine groups such as Tris, or carrier proteins such as BSA.  pause poInt The conjugates can be kept at 4 °C for up to 6 months.
sample preparation • tIMInG 30 min 19| Dilute samples such as plasma, serum or whole blood tenfold in PLA buffer. Each spPLA reaction requires 45 µl of diluted sample.
20|
Prepare a dilution series of recombinant protein in PLA buffer as described in the INTRODUCTION. We recommend using recombinant protein dilution series in tenfold increments ranging from low-fM concentrations to 1 or 10 nM.
capturing target protein on microparticles • tIMInG 2 h 21| Vortex the antibody-coated microparticles prepared in Steps 1-9 to achieve a homogeneous suspension.
22|
For one singleplex PLA reaction, pipette 1 µl of the antibody-coated microparticle suspension. For one multiplex PLA reaction, pipette 0.1 µl of each bead suspension functionalized with different capture antibodies.  crItIcal step For multiplex PLA, a master mix of all beads is usually prepared to avoid the necessity of pipetting 0.1 µl. However, beads can be further diluted to allow reliable pipetting. 
28|
Incubate the concentrated probes for 1 h at RT.
29|
Dilute the two concentrated probe mixes 100-fold in PLA buffer and incubate them for 5 min at RT.  crItIcal step When streptavidin-conjugated oligonucleotides (SLC1 and SLC2) are coupled to biotinylated antibodies, each PLA probe must be prepared and incubated in a separate tube. This is to avoid SLC1 and SLC2 binding to the same antibody, something that would give rise to increased assay background. The two PLA probes must be kept separate until they have been incubated with PLA buffer (containing free biotin) that blocks biotin-binding sites on SLC1 and SLC2.  pause poInt We recommend preparing probes before every experiment. Alternatively, probes can be stored at 4 °C for time periods not exceeding a week.
30|
Mix the two probes in one microcentrifuge tube. The final concentration of each probe should be 250 pM. For the multiplex PLA, mix covalent conjugates in one microcentrifuge tube to a final concentration of 250 pM for each probe.
Detection of captured proteins • tIMInG 2 h 31| After incubation at
Step 25, wash the beads twice with 100 µl of washing buffer: spin down the plate or strip in a plate centrifuge (1,000g for 5 s at RT) to collect all of the liquid at the bottom of the wells. Put the plate or strip on a 96-well plate magnet for 30 s until all the beads form a pellet by the side of the tubes. Discard the supernatant and add 100 µl of washing buffer into each well with a multichannel pipette. Let the plate or strip stand on the magnet for 30 s before removing the liquid. Repeat this step once.
32|
Add 50 µl of probe mix prepared in
Step 30 into each well. Vortex samples to obtain a homogeneous solution in each well. 
33|

